.jpg)
To understand Stratus, it helps to start with some basic microbiology. COVID-19 is caused by a virus called SARS-CoV-2. Like many viruses, it changes over time. As it makes copies of itself in people’s bodies, small mistakes (mutations) can occur in the virus’s genetic code. Most mutations don’t matter much, but occasionally one gives the virus an advantage—for example, making it spread more easily, or helping it partly dodge our immune defenses.
When a version of the virus has such changes, scientists label it a variant (sometimes a variant of interest, or a variant under monitoring). Over the course of the pandemic, we’ve seen many such variants: alpha, delta, omicron and many sub‐variants of omicron. The variant known as Stratus is one of the more recent ones that has gained attention.
The variant is officially labeled XFG, and the nickname “Stratus” is commonly used.
It’s a recombinant variant, meaning it is derived from two earlier omicron sub‐variants.
Stratus was first detected in January 2025 in Southeast Asia.
By June 2025, it had spread to at least 38 countries.
In the U.S., CDC data suggests Stratus is responsible for a significant proportion of current COVID cases. Estimates vary, but some reports put it at around 70 to 78 percent, or at least a large share, of circulating virus.
The World Health Organization (WHO) has designated XFG/Stratus as a “variant under monitoring.” That means the WHO is keeping an eye on it for changes in transmission, severity or vaccine evasion, but it is not (as of now) labeled a variant of concern.
Health agencies in different countries, like the U.S. CDC and the UK Health Security Agency (UKHSA), are also tracking its spread. Stratus is globally spreading, a recently emerged COVID variant with enough mutations to attract attention but not yet flagged for extreme risk.
Every new variant is “different” in some ways. The question is: how much different, and in what ways.
It carries several mutations, especially in the spike protein (the part the virus uses to latch onto and enter human cells). Some of these changes are thought to help it evade immunity somewhat, meaning our body’s immune defenses (from prior infection or vaccination) might be slightly less effective in stopping it.
Current data does not suggest that Stratus causes more serious disease, more hospitalizations or more deaths. Health agencies generally classify its additional immune evasion as a small increase in the virus’s ability to avoid being recognized by the immune system.
The symptoms of Stratus are largely similar to those for COVID in general: fever, cough, sore throat, nasal congestion or runny nose, fatigue, body aches, headache, and sometimes digestive symptoms like nausea or diarrhea.
One distinctive symptom that has emerged is hoarseness or a raspy voice. Some reports suggest that a dry, irritated throat and hoarseness are particularly common with Stratus infections.
That said, having a hoarse voice isn’t unique to COVID; it can happen with many viral respiratory infections. It’s not a perfect identifier.
Stratus appears to spread quite readily, and in many places, it is becoming dominant among COVID cases.
It is considered slightly more contagious than earlier variants, but not dramatically so.
Because many people are no longer regularly testing (especially mild cases), tracking exact prevalence is harder, but analyses of wastewater, hospital data and sequencing suggest Stratus is rising in many areas. Some of the mutations in Stratus may help it partially evade antibodies from prior infection or vaccination, meaning it might infect people who have some immunity, although likely it would cause milder illness.
Importantly, based on current assessments, existing COVID-19 vaccines are expected to remain effective, especially in preventing severe disease, hospitalization and death.
Because Stratus is relatively new, many questions remain. Here’s what is known, and what we don’t yet know.
Public health risk is currently rated low.
The WHO has placed Stratus under monitoring, not concern.
As with prior variants, people who are vaccinated (especially boosted) are much less likely to get severely ill. Stratus does not seem to overcome this protection entirely.
Because of the partial immune evasion, there may be more breakthrough infections (infections in vaccinated people) or reinfections. Still, most of these will likely be mild.
The hoarseness/voice changes as a marker
is unusual enough that health agencies are paying attention to it as a possible red flag for the Stratus variant.
Severity in at‐risk populations.
Most of the data so far reflect general populations. How Stratus behaves in older adults, the immunocompromised or people with chronic diseases is less certain.
Vaccination and boosters
Even if Stratus reduces vaccine effectiveness against mild infection a bit, the protection for more serious outcomes is likely to remain strong (based on current assessments).
Especially with respiratory or cold/flu-like symptoms (fever, cough, sore throat, fatigue) or hoarseness, consider getting tested for COVID. Early detection helps with isolation.
YES, but make sure you check the expiration date of the test kit.
The emergence of Stratus is a reminder that COVID-19 is not “over”; the virus continues to adapt. But it’s also a sign that our tools (vaccines, public health surveillance, diagnostics) still work. The fact that we’re catching and tracking variants like this, rather than being surprised, is a mark of progress.
For most healthy individuals, Stratus is unlikely to pose a drastically higher threat than previous omicron variants. But in vulnerable populations and in settings where transmission is high, caution remains justified.
No one needs to get sick or die from any disease that is preventable, or may have non-life-threatening symptoms, by VACCINATION.
Your health is your decision, not Washington’s.
Michael Kossove is professor emeritus and adjunct professor of microbiology at Touro University’s School of Health Sciences.
Comments
No comments on this item Please log in to comment by clicking here